The Next Pharma Battleground: Can India Unlock the Affordable GLP-1 Market?

 

BIZ MASALA  |  PHARMA & MARKETS

As generic semaglutide reshapes the market, the real contest moves from launch-day buzz to affordability, quality and patient continuity.

By Murthy ASR | Biz Masala

Illustrative editorial image: pharmaceutical quality control and injectable-medicine manufacturing. It does not depict a named company or a specific GLP-1 product.

The price barrier is beginning to crack

India’s GLP-1 story has entered a new phase. For years, medicines in this fast-growing class were associated with high prices, specialist prescriptions and a relatively narrow pool of patients able to sustain treatment. The expiry in March 2026 of Novo Nordisk’s Indian patent on semaglutide opened the door to a wave of domestic generic launches. The opportunity is substantial—but the next chapter will not be decided by launch announcements alone.

Semaglutide is the active ingredient in medicines including Ozempic and Wegovy. GLP-1 receptor agonists are used in the management of type 2 diabetes and, for certain products and indications, obesity. They are not interchangeable as a class: approvals, formulations, dosing, indications and intellectual-property positions differ by molecule and product. India’s semaglutide patent expiry should therefore not be read as a blanket expiry for every GLP-1 medicine.

Reuters reported in March that Indian manufacturers were preparing a broad wave of lower-priced semaglutide brands after the patent expiry. The shift is already visible in sales data: a Business Standard report citing Pharmarack’s PharmaTrac said monthly semaglutide volumes rose from about 114,000 units in February to 434,000 in September 2026. Generic brands accounted for roughly 74% of monthly units by September.

A market growing faster in volume than value

Source: Business Standard, citing Pharmarack PharmaTrac, reported 13 October 2026. Units shown in thousands.

Reported monthly sales value rose from ₹48 crore in February to ₹113 crore in September 2026; volume growth outpaced value growth as lower-priced generics expanded.

The figures point to a familiar genericisation pattern: more units are reaching the market, while prices and the mix of products influence the value captured by manufacturers. For patients, cheaper options may improve access—but only if products are appropriately prescribed, supplied consistently and manufactured to reliable quality standards. For companies, a fast-growing category can still become a hard business if pricing pressure erodes margins or production problems disrupt supply.

The prize is large—but forecasts are not guarantees

On 23 October 2026, Reuters reported a J.P. Morgan estimate that the combined GLP-1 market in China, India and Brazil could expand from $6.6 billion currently to $22 billion by 2035, implying roughly 15% annual growth. That is a regional estimate, not an India-only forecast. J.P. Morgan described India as an under-penetrated market, with uptake held back by affordability, hesitation around injections and cultural attitudes.

The growth case rests on several moving parts: lower prices, a larger prescribing base, better availability, patient persistence and the ability of manufacturers to deliver consistent quality at scale. A large diabetes and obesity burden creates potential demand; it does not automatically translate into paid prescriptions or long-term treatment.

Who could benefit in India?

The competitive field spans established branded-drug companies, generic manufacturers and businesses with capabilities in active pharmaceutical ingredients, peptides, sterile manufacturing, devices and cold-chain logistics. Reuters’ October report cited J.P. Morgan’s view that Divi’s Laboratories and Torrent Pharmaceuticals could offer exposure to the theme. That is an analyst view—not a guarantee of performance, and not a recommendation to buy either stock.

Generic launches can win attention quickly, but durable advantage may depend on less visible strengths: dependable active-ingredient supply, process control, regulatory compliance, device usability, physician confidence, distribution reach and the ability to support patients through a chronic treatment journey. The field is crowded, and a brand name or early sales spike alone is not proof of a lasting franchise.

Quality and supply are now competitive issues

The market’s growth also exposes the cost of execution failures. Reuters reported in July that Dr. Reddy’s Laboratories had paused new semaglutide batches after an impurity issue in an active ingredient, with supply disruptions expected to last into late October; Torrent also recalled selected batches for technical evaluation. The episode is a reminder that scaling a complex injectable is not the same as launching a conventional tablet. Quality systems, batch consistency and transparent communication can directly affect patient confidence and commercial momentum.

Regulators and clinicians also face a challenge: demand can outpace public understanding. These medicines are not cosmetic shortcuts or casual wellness products. They can have side effects and require clinical assessment, appropriate prescribing, follow-up and attention to product authenticity. Consumers should not self-medicate, buy from unverified online sellers or change doses without medical advice.

The next test: access that lasts

India’s opportunity is not simply to make GLP-1 medicines cheaper. It is to build a dependable market in which eligible patients can access appropriately approved treatments and continue them safely when clinically indicated. That means balancing price competition with quality, supply reliability, physician education and sensible patient expectations.

The first phase was about who could launch after semaglutide’s patent expiry. The next phase is more demanding: who can manufacture consistently, earn trust, reach patients responsibly and remain viable as prices come under pressure? In that contest, the winners may be decided less by the loudest launch and more by the quiet discipline of quality and execution.

Key numbers at a glance

Indicator	Reported figure	What it suggests
Semaglutide monthly volume	114,000 (Feb) → 434,000 (Sep 2026)	Rapid unit expansion after generic entry
Generic share of monthly units	About 74% in Sep 2026	Generics dominate unit volume
Monthly market value	₹48 crore (Feb) → ₹113 crore (Sep)	Value grew, but less sharply than units
China–India–Brazil GLP-1 market	$6.6bn currently → $22bn by 2035 (J.P. Morgan estimate)	Regional forecast; not India alone

Sources and editorial notes

·       Reuters, 23 October 2026, “GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says.”

·       Business Standard, 13 October 2026, “Semaglutide mkt settles into steady growth six months after patent expiry,” citing Pharmarack PharmaTrac.

·       Reuters, 19 March 2026, “Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India.”

·       Reuters, 9 July 2026, “India’s Dr Reddy’s says semaglutide shipping disruption to last until at least late October.”

Editorial note: Market figures and forecasts are attributed to the cited reports and should be read in that context. The hero image is illustrative. This article is business journalism, not medical advice or investment advice.

 

— END OF STORY —

Biz Masala | Business stories, decoded.